ASXL1 and Buschke-Ollendorff syndrome: Matheus et al. used iPSC lines derived from two BOS patients, in conjunction with four biologically-independent ASXL1 lines that were created via genome editing, to study dosage (heterozygous vs homozygous) and the effect of overexpression of the full-length and truncated mutant.